Who owns Korsana Biosciences, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of KRSA from SEC Form 13F filings across 44 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 44 institutions disclosed 39.5M shares of Korsana Biosciences, Inc. worth $1.27B — about 292% of shares outstanding; the largest disclosed holder is Fairmount Funds Management LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
44
13F holders
$1.27B
value, 2026 filers
292%
of shares outstanding (39.5M sh)
44
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of KRSA's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Fairmount Funds Management LLCNEW | 9.1M | $291.3M | 18.3% | 67.3% | new |
| 2 | TCG Crossover Management, LLCNEW | 4.5M | $145.6M | 4.1% | 33.6% | new |
| 3 | Venrock Adviser, LLCNEW | 4.5M | $145.6M | 7.1% | 33.6% | new |
| 4 | FMR LLCNEW | 3.2M | $102.4M | 0.0% | 23.7% | new |
| 5 | JPMORGAN CHASE & CONEW | 2.7M | $91.4M | 0.0% | 19.9% | new |
| 6 | FCPM III SERVICES B.V.NEW | 2.2M | $70.1M | 6.6% | 16.2% | new |
| 7 | SanofiNEW | 2.0M | $63.8M | 10.1% | 14.7% | new |
| 8 | Foresite Capital Management VI LLCNEW | 1.4M | $45.8M | 8.1% | 10.6% | new |
| 9 | GENERAL ATLANTIC, L.P.NEW | 1.4M | $43.7M | 1.8% | 10.1% | new |
| 10 | RA CAPITAL MANAGEMENT, L.P.NEW | 892,743 | $28.6M | 0.3% | 6.6% | new |
| 11 | Commodore Capital LPNEW | 877,022 | $28.1M | 2.2% | 6.5% | new |
| 12 | Vivo Capital, LLCNEW | 877,020 | $28.1M | 3.1% | 6.5% | new |
| 13 | RTW INVESTMENTS, LPNEW | 877,020 | $28.1M | 0.3% | 6.5% | new |
| 14 | Janus Henderson Group Ltd.NEW | 789,319 | $25.3M | 0.0% | 5.8% | new |
| 15 | SR ONE CAPITAL MANAGEMENT, LPNEW | 613,915 | $19.6M | 1.7% | 4.5% | new |
| 16 | Paradigm Biocapital Advisors LPNEW | 613,914 | $19.6M | 0.4% | 4.5% | new |
| 17 | Remedium Capital Partners, LLCNEW | 518,500 | $16.6M | 6.1% | 3.8% | new |
| 18 | Kalehua Capital Management LLCNEW | 442,653 | $14.2M | 10.7% | 3.3% | new |
| 19 | Spruce Street Capital LPNEW | 338,951 | $10.3M | 1.6% | 2.5% | new |
| 20 | Duquesne Family Office LLCNEW | 278,561 | $8.9M | 0.2% | 2.1% | new |
| 21 | Affinity Asset Advisors, LLCNEW | 263,106 | $8.4M | 0.3% | 1.9% | new |
| 22 | Vestal Point Capital, LPNEW | 263,105 | $8.4M | 0.2% | 1.9% | new |
| 23 | Woodline Partners LPNEW | 219,255 | $7.0M | 0.0% | 1.6% | new |
| 24 | NEXTBio Capital Management LPNEW | 175,403 | $5.6M | 2.4% | 1.3% | new |
| 25 | MARSHALL WACE, LLPNEW | 131,552 | $4.2M | 0.0% | 1% | new |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.